-
公开(公告)号：US09700565B2
公开(公告)日：2017-07-11
申请号：US14928223
申请日：2015-10-30
IPC分类号： A61K31/553
CPC分类号： A61K31/553
摘要： The present invention relates to a method of treating a warm-blooded animal, especially a human, having Mixed Lineage Leukemia (MLL rearranged ALL) comprising administering to said animal a therapeutically effective amount of a staurosporine derivative, especially PKC412 or a pharmaceutically acceptable salt thereof, alone or in combination with further therapeutic measures, for example, those defined herein; to the use of a staurosporine derivative for the preparation of a medicament for the treatment of MLL rearranged ALL; and to a commercial package comprising a staurosporine derivative together with instructions for its use in the treatment of MLL rearranged ALL.
-
公开(公告)号：US20170209458A9
公开(公告)日：2017-07-27
申请号：US14928223
申请日：2015-10-30
IPC分类号： A61K31/553
CPC分类号： A61K31/553
摘要： The present invention relates to a method of treating a warm-blooded animal, especially a human, having Mixed Lineage Leukemia (MLL rearranged ALL) comprising administering to said animal a therapeutically effective amount of a staurosporine derivative, especially PKC412 or a pharmaceutically acceptable salt thereof, alone or in combination with further therapeutic measures, for example, those defined herein; to the use of a staurosporine derivative for the preparation of a medicament for the treatment of MLL rearranged ALL; and to a commercial package comprising a staurosporine derivative together with instructions for its use in the treatment of MLL rearranged ALL.
-
3.发明申请Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias 有权治疗混合谱系白血病基因重排的急性淋巴细胞性白血病的方法公开(公告)号：US20160184319A1
公开(公告)日：2016-06-30
申请号：US14928223
申请日：2015-10-30
IPC分类号： A61K31/553
CPC分类号： A61K31/553
摘要： The present invention relates to a method of treating a warm-blooded animal, especially a human, having Mixed Lineage Leukemia (MLL rearranged ALL) comprising administering to said animal a therapeutically effective amount of a staurosporine derivative, especially PKC412 or a pharmaceutically acceptable salt thereof, alone or in combination with further therapeutic measures, for example, those defined herein; to the use of a staurosporine derivative for the preparation of a medicament for the treatment of MLL rearranged ALL; and to a commercial package comprising a staurosporine derivative together with instructions for its use in the treatment of MLL rearranged ALL.
摘要翻译： 本发明涉及治疗具有混合谱系白血病（MLL重排ALL）的温血动物，特别是人的方法，包括向所述动物施用治疗有效量的星形孢菌素衍生物，特别是PKC412或其药学上可接受的盐 单独或与另外的治疗措施结合使用，例如本文定义的那些; 使用星孢菌素衍生物制备用于治疗MLL重排ALL的药物; 以及包含星形孢菌素衍生物的商业包装以及用于治疗MLL重新排列的ALL的说明书。
-
4.发明申请Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias 审中-公开治疗混合谱系白血病基因重排的急性淋巴细胞性白血病的方法公开(公告)号：US20140303146A1
公开(公告)日：2014-10-09
申请号：US14311834
申请日：2014-06-23
IPC分类号： A61K31/553
CPC分类号： A61K31/553
摘要： The present invention relates to a method of treating a warm-blooded animal, especially a human, having Mixed Lineage Leukemia (MLL rearranged ALL) comprising administering to said animal a therapeutically effective amount of a staurosporine derivative, especially PKC412 or a pharmaceutically acceptable salt thereof, alone or in combination with further therapeutic measures, for example, those defined herein; to the use of a staurosporine derivative for the preparation of a medicament for the treatment of MLL rearranged ALL; and to a commercial package comprising a staurosporine derivative together with instructions for its use in the treatment of MLL rearranged ALL.
摘要翻译： 本发明涉及治疗具有混合谱系白血病（MLL重排ALL）的温血动物，特别是人的方法，包括向所述动物施用治疗有效量的星形孢菌素衍生物，特别是PKC412或其药学上可接受的盐 单独或与另外的治疗措施结合使用，例如本文定义的那些; 使用星孢菌素衍生物制备用于治疗MLL重排ALL的药物; 以及包含星形孢菌素衍生物的商业包装以及用于治疗MLL重新排列的ALL的说明书。
-
5.发明申请METHOD OF TREATING MIXED LINEAGE LEUKEMIA GENE-REARRANGED ACUTE LYMPHOBLASTIC LEUKEMIAS 审中-公开治疗混合型淋巴细胞白血病基因突变型急性淋巴细胞白血病的方法公开(公告)号：US20140057897A1
公开(公告)日：2014-02-27
申请号：US14068017
申请日：2013-10-31
IPC分类号： A61K31/553
CPC分类号： A61K31/553
摘要： The present invention relates to a method of treating a warm-blooded animal, especially a human, having Mixed Lineage Leukemia (MLL rearranged ALL) comprising administering to said animal a therapeutically effective amount of a staurosporine derivative, especially PKC412 or a pharmaceutically acceptable salt thereof, alone or in combination with further therapeutic measures, for example, those defined herein; to the use of a staurosporine derivative for the preparation of a medicament for the treatment of MLL rearranged ALL; and to a commercial package comprising a staurosporine derivative together with instructions for its use in the treatment of MLL rearranged ALL.
摘要翻译： 本发明涉及治疗具有混合谱系白血病（MLL重排ALL）的温血动物，特别是人的方法，包括向所述动物施用治疗有效量的星形孢菌素衍生物，特别是PKC412或其药学上可接受的盐 单独或与另外的治疗措施结合使用，例如本文定义的那些; 使用星孢菌素衍生物制备用于治疗MLL重排ALL的药物; 以及包含星形孢菌素衍生物的商业包装以及用于治疗MLL重新排列的ALL的说明书。
-
6.发明申请Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias 审中-公开治疗混合谱系白血病基因重排的急性淋巴细胞性白血病的方法公开(公告)号：US20080221080A1
公开(公告)日：2008-09-11
申请号：US10569708
申请日：2003-08-25
IPC分类号： A61K31/553 , A61P35/02
CPC分类号： A61K31/553
摘要： The present invention relates to a method of treating a warm-blooded animal, especially a human, having Mixed Lineage Leukemia (MLL rearranged ALL) comprising administering to said animal a therapeutically effective amount of a staurosporine derivative, especially PKC412 or a pharmaceutically acceptable salt thereof, alone or in combination with further therapeutic measures, for example, those defined herein; to the use of a staurosporine derivative for the preparation of a medicament for the treatment of MLL rearranged ALL; and to a commercial package comprising a staurosporine derivative together with instructions for its use in the treatment of MLL rearranged ALL.
摘要翻译： 本发明涉及治疗具有混合谱系白血病（MLL重排ALL）的温血动物，特别是人的方法，包括向所述动物施用治疗有效量的星形孢菌素衍生物，特别是PKC412或其药学上可接受的盐 单独或与另外的治疗措施结合使用，例如本文所定义的那些; 使用星孢菌素衍生物制备用于治疗MLL重排ALL的药物; 以及包含星形孢菌素衍生物的商业包装以及用于治疗MLL重新排列的ALL的说明书。
-
7.发明申请Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias 审中-公开治疗混合谱系白血病基因重排的急性淋巴细胞性白血病的方法公开(公告)号：US20120329779A1
公开(公告)日：2012-12-27
申请号：US13606070
申请日：2012-09-07
IPC分类号： A61K31/553 , C07D498/18 , A61P35/02
CPC分类号： A61K31/553
摘要： The present invention relates to a method of treating a warm-blooded animal, especially a human, having Mixed Lineage Leukemia (MLL rearranged ALL) comprising administering to said animal a therapeutically effective amount of a staurosporine derivative, especially PKC412 or a pharmaceutically acceptable salt thereof, alone or in combination with further therapeutic measures, for example, those defined herein; to the use of a staurosporine derivative for the preparation of a medicament for the treatment of MLL rearranged ALL; and to a commercial package comprising a staurosporine derivative together with instructions for its use in the treatment of MLL rearranged ALL.
摘要翻译： 本发明涉及治疗具有混合谱系白血病（MLL重排ALL）的温血动物，特别是人的方法，包括向所述动物施用治疗有效量的星形孢菌素衍生物，特别是PKC412或其药学上可接受的盐 单独或与另外的治疗措施结合使用，例如本文定义的那些; 使用星孢菌素衍生物制备用于治疗MLL重排ALL的药物; 以及包含星形孢菌素衍生物的商业包装以及用于治疗MLL重新排列的ALL的说明书。
-
8.发明申请METHOD OF TREATING MIXED LINEAGE LEUKEMIA GENE-REARRANGED ACUTE LYMPHOBLASTIC LEUKEMIAS 审中-公开治疗混合型淋巴细胞白血病基因突变型急性淋巴细胞白血病的方法公开(公告)号：US20110009383A1
公开(公告)日：2011-01-13
申请号：US12877604
申请日：2010-09-08
IPC分类号： A61K31/553 , A61P35/04
CPC分类号： A61K31/553
摘要： The present invention relates to a method of treating a warm-blooded animal, especially a human, having Mixed Lineage Leukemia (MLL rearranged ALL) comprising administering to said animal a therapeutically effective amount of a staurosporine derivative, especially PKC412 or a pharmaceutically acceptable salt thereof, alone or in combination with further therapeutic measures, for example, those defined herein; to the use of a staurosporine derivative for the preparation of a medicament for the treatment of MLL rearranged ALL; and to a commercial package comprising a staurosporine derivative together with instructions for its use in the treatment of MLL rearranged ALL.
摘要翻译： 本发明涉及治疗具有混合谱系白血病（MLL重排ALL）的温血动物，特别是人的方法，包括向所述动物施用治疗有效量的星形孢菌素衍生物，特别是PKC412或其药学上可接受的盐 单独或与另外的治疗措施结合使用，例如本文定义的那些; 使用星孢菌素衍生物制备用于治疗MLL重排ALL的药物; 以及包含星形孢菌素衍生物的商业包装以及用于治疗MLL重新排列的ALL的说明书。
-
9.发明申请Use of c-Src inhibitors alone or in combinaton with STI571 for the treatment of leukaemia 审中-公开单独使用c-Src抑制剂或与STI571组合用于治疗白血病公开(公告)号：US20070027167A1
公开(公告)日：2007-02-01
申请号：US11515981
申请日：2006-09-05
申请人： Nicholas Donato , Doriano Fabbro , Paul Manley , Jurgen Mestan , Markus Warmuth , Michael Hallek , Moshe Talpaz , Ji Wu
发明人： Nicholas Donato , Doriano Fabbro , Paul Manley , Jurgen Mestan , Markus Warmuth , Michael Hallek , Moshe Talpaz , Ji Wu
IPC分类号： A61K31/519
CPC分类号： A61K35/02 , A61K31/506 , A61K31/519
摘要： The invention relates to a combination which comprises (a) at least one compound decreasing the c-Src activity and (b) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamdio]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine or the monomethanesulfonate salt thereof; to pharmaceutical compositions comprising said combinations; and to a method of treating a warm-blooded animal having leukaemia, especially chronic myelogenous leukaemia, comprising administering to the animal at least one compound inhibiting the activity of a member of the Src kinase family, the Tec kinase family or a Raf kinase inhibitor, in particular inhibiting the c-Src protein tyrosine kinase activity or inhibiting simultaneously the c-Src protein tyrosine kinase activity and the Bcr-Abl tyrosine kinase activity, alone or in combination with a Bcr-Abl inhibitor, in particular N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine.
摘要翻译： 本发明涉及一种组合，其包含（a）至少一种降低c-Src活性的化合物和（b）N- {5- [4-（4-甲基 - 哌嗪基 - 甲基） - 苯甲酰氨基] -2-甲基苯基} -4-（3-吡啶基）-2-嘧啶胺或其单甲磺酸盐; 包含所述组合的药物组合物; 以及治疗具有白血病，特别是慢性骨髓性白血病的温血动物的方法，包括向所述动物施用至少一种抑制Src激酶家族成员，Tec激酶家族或Raf激酶抑制剂的活性的化合物， 特别是抑制c-Src蛋白酪氨酸激酶活性或同时抑制c-Src蛋白酪氨酸激酶活性和Bcr-Abl酪氨酸激酶活性，单独或与Bcr-Abl抑制剂组合，特别是N- {5- [ 4-（4-甲基 - 哌嗪子基 - 甲基） - 苯甲酰氨基] -2-甲基苯基} -4-（3-吡啶基）-2-嘧啶胺。
-
公开(公告)号：US06291668B1
公开(公告)日：2001-09-18
申请号：US09445486
申请日：1999-12-07
IPC分类号： C07H2104
CPC分类号： C12N15/113 , A61K38/00 , C12N2310/315 , C12N2310/321 , C12N2310/33 , C12N2310/332 , C12N2310/346 , C12N2310/3521 , C12N2310/3525 , C12N2310/3527
摘要： The present invention relates to an oligonucleotide derivative which is specifically hybridizable to a region of a RNA deriving from the gene encoding human Bcl-2 protein, the region being selected from the group consisting of a region comprising a sequence corresponding to a sequence ranging from base position no. 1880 (5′) to no. 1899 (3′), or comprising at least a part thereof, of the human Bcl-2 cDNA, and a region comprising the translation termination codon of the RNA.
摘要翻译： 本发明涉及与衍生自编码人Bcl-2蛋白的基因的RNA区域特异性杂交的寡核苷酸衍生物，所述区域选自包含对应于碱基的序列的序列的区域 职位号 1880（5'）到否 1899（3'），或其至少部分包含人Bcl-2 cDNA，以及包含RNA翻译终止密码子的区域。
-
-
-
-
-
-
-
-
-
搜索结果
27 条记录 (耗时 0.019 秒)
